Anne Gadegaard, Global Senior Advisor of Novo Nordisk has delivered a presentation highlighting the policy of Triple Bottom Line: Financially Responsible, Socially Responsible, Environmentally Responsible at the dialogue on “Fostering Sustainable Procurement: How Procurers Can Change the Global Health Sector” in UN City, Copenhagen.

1. Sustainable
supply chains
in the global
health aid
market
Novo Nordisk
Anne Gadegaard
Senior global advisor

2. Novo Nordisk
at a glance
Novo Nordisk is a global
healthcare company with more
than 90 years of innovation and
leadership in diabetes care
This heritage has given us
experience and capabilities that
also enable us to help people
defeat other serious chronic
conditions: haemophilia, growth
disorders and obesity
Signatory to UN Global Compact
since 2002.
Private sector insight 2
2
Novo
Nordisk -
Corporate
Presentatio
n
11 May 2016
PRODUCTS MARKETED IN
180 COUNTRIES
STRATEGIC
PRODUCTION SITES
IN BRAZIL, CHINA, DENMARK,
FRANCE AND US
SUPPLIER OF MORE THAN
HALF OF THE
WORLD’S INSULIN
26,800,000
PEOPLE USE OUR PRODUCTS
AFFILIATES IN
COUNTRIES
R&D CENTRES
IN CHINA, DENMARK,
INDIA AND US
DKK 107.9
BILLION
IN TOTAL REVENUE
APPROXIMATELY
230,000
SHAREHOLDERS
75
EMPLOYS APPROXIMATELY
41,000 PEOPLEDIABETES
OBESITY
GROWTH
DISORDERS
HAEMOPHILIA

3. TBL is integrated in our business decisions
Private sector insight 11 May 2016 3
Novo Nordisk Way The Triple Bottom Line Articles of Association
2. Objects
The Company’s objects are to carry
out research and development and to
manufacture and commercialise
pharmaceutical, medical and technical
products and services as well as any
other activity related thereto as
determined by the Board of Directors.
The Company strives to conduct
its activities in a financially,
environmentally, and socially
responsible way.

4. The Triple Bottom Line is…
Private sector insight 11 May 2016 4
… a mind-set … core of our business
It is a lens we use for
decision making in Novo
Nordisk
… investors & patients
It is also about ensuring
that the interests of our
shareholders, employees
and patients are accounted
for
It is our business, when we
research, produce and
commercialise our products

5. TBL is about staying in
business for the long
term
“As most companies, we have a financial
bottom line but we also have a social and
an environmental bottom line. Because if
you look at your business in a long enough
time perspective, then social and
environmental issues become financial
issues.”
Lars Rebien Sørensen,
President and Chief Executive Officer

6. Triple Bottom Line is good business
The business case as a result of energy saving
projects in
Total savings
Total investment
Total net savings
2.0 Average payback
265,000
tons CO2
Mill DKK
-50
0
50
100
150
200
250
-50
-25
0
25
50
75
100
125
150
175
200
225
250
275
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
Business case from projects realised in 2005 - 2014
Investment Renewable energy
11 May 2016Private sector insight 6

7. UN Global Compact on the SDGs
Private sector insight 11 May 2016 7

8. Novo Nordisk Responsible Sourcing Model
Private sector insight 11 May 2016 8

9. Supplier Audits
• Qualification & follow up audits
• Audits per year to cover:
• Producers
• Agents
• Service Providers
• Self Assessment Questionnaire
• Supplier Engagement activities
Programme overview
We drive responsible sourcing
practices in Novo Nordisk to build
resilient supply chains and
support business growth.
Must win battles:
1. Map supply chain risks via cost
effective processes
2. Mitigate risk with key high risk
suppliers
3. Increase leverage through
collaboration
Activities:
• Operational RS tasks
• Programme development
activities
• Reporting on internal/ external
requirements
Private sector insight 11 May 2016 9
Strategy 2016-2018 Model Tools
RS Standards and clause
• All new suppliers with contract
• Business Ethics
• Labour Rights
• Health & Safety
• Environment
• Management Systems
Mediu
m risk
High
risk
Low
risk
Mediu
m risk
Risk impact
Risklikelihood
One risk model applied differently in
the three sourcing areas

10. Diabetes management care pathway
• Understanding the trade-
off
Private sector insight 11 May 2016 10
Good
management
Greater healthcare costs and
carbon emissions now
But fewer costs and carbon
emissions in the future due
to reduced risk of
complications
Poor
management
Fewer healthcare costs and
carbon emissions now
But greater costs and carbon
emissions in the future due to
reduced risk of complications

11. Product and patient carbon footprint
Private sector insight 11 May 2016 11
Product
Carbon
Footprint
Raw Materials Manufacturing Distribution Use Waste
Patient Carbon
Footprint
Product
Carbon
Footprint*
Blood Glucose
Monitoring
Care
Management
Other
Medication
Hospital

12. Good management may lead to
reduced carbon emissions
Private sector insight 11 May 2016 12
Summary
Good management of type 2 diabetes
• increases the life expectancy by 0.57 years (ΔQALY = 0.54)
• reduces the patient carbon footprint by 3%

13. Detailed analyses enable us to identify the
main contributors to the carbon emissions
Private sector insight 11 May 2016 13
Contribution to CO2e per complication Contribution to CO2e per module

14. We can also identify what causes carbon
emissions to vary across treatment profiles
Private sector insight 11 May 2016 14
Summary
Poor management is
associated with:
• more inpatient admissions
and bed days
• less use of pharmaceuticals
and blood glucose tests

15. Conclusions from the pilot study
Private sector insight 11 May 2016 15
Good management increases the
patient lifetime, but may reduce the
patient carbon footprint
1. Exploring patient carbon
footprint
With the right data, it is possible to
make detailed analyses of the patient
carbon footprint
2. Testing the method

16. For more information:
novonordisk.com/sustainability twitter.com/novonordiskTBL
The Apis bull logo is a registered trademark of Novo Nordisk A/S